ВестникНОМУС
.
Сборникматериаловнаучной
сессии
-2013
359
12. HessCW,MillsKR,MurrayNM, Schriefer TN.Magnetic brain stimulation:
centralmotor conduction studies inmultiple sclerosis. AnnNeurol 1987; 22: 744–
52.
13. KandlerRH, Jarratt JA, Davies-JonesG, Gumpert EJ, VenablesGS, SagarHJ,
et al. The role ofmagnetic stimulation as a quantifier ofmotor disability in patients
withmultiple sclerosis. JNeurol Sci 1991; 106: 31–4.
14. Kurtzke J.F. Ratingneurologic impairment inmultiple sclerosis: an expanded
disability status scale (EDSS)Neurology. 1983Nov;33(11):1444-52.
15. LiewFY,McInnes IB. Role of interleukin15 and interleukin 18 in
inflammatory response. AnnRheumDis. 2002;61 (Suppl 2): ii100-2.
16. Nagai Y, OgasawaraH, TaketaY, AsoH, KanayaT,MiyakeM,WatanabeK,
OhwadaS,MunetaY, Yamaguchi T. Expressionof inflammatory-related factors in
porcine anterior pituitary-derived cell line. Vet Immunol
Immunopathol. 2008;124:201–208. doi: 10.1016/j.vetimm.2008.03.007.
17. Nagai Y, OgasawaraH, TaketaY, AsoH, TanakaS, KanayaT,WatanabeK,
OhwadaS,MunetaY, Yamaguchi T. Bovine anterior pituitaryprogenitor cell line
expresses interleukin (IL)-18 and IL-18 receptor. J
Neuroendocrinol. 2008;20:1233–1241. doi: 10.1111/j.1365-2826.2008.01779.x.
18. NolanKF, GreavesDR,WaldmannH. The human interleukin 18 gene IL-18
maps to 11q22.2-q22.3, closely linked to theDRD2 gene locus anddistinct from
mapped IDDM loci.Genomics. 1998; 51(1): 161-163.
19.
Luessi F
,
SiffrinV
,
ZippF
. Neurodegeneration inmultiple sclerosis: novel
treatment strategies.
Expert RevNeurother.
2012Sep;12(9):1061-77.
20. PolmanC.H. et al. Diagnostic criteria formultiple sclerosis: 2005 revisions to
the "McDonaldCriteria". AnnNeurol. 2005Dec;58(6):840-6.
21. ReddyP. Interleukin-18: recent advances. CurrOpinHematol. 2004; 11 (6):
405-10.
22. Salle JY, Hugon J, TabaraudF, Boulestieux JM, Vallat JM, DumasM, et al.
Improvement inmotor evokedpotentials and clinical course post-steroid therapy
inmultiple sclerosis. JNeurol Sci 1992; 108: 184–8.
